Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
L-TryptophanPDL

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

I DEC / 13
Labetalol or its saltsPDL I DEC / 13
Lacosamide or its derivativesPDL I DEC / 13
Lactic acidPDL

When recommended for parenteral use as a tissue sclerosing agent.

I DEC / 13
Lactulose III SEP / 98
Lamivudine or its saltsPDL I DEC / 13
Lamotrigine or its saltsPDL I DEC / 13
LanadelumabPDL I NOV / 18
Lanreotide or its saltsPDL I DEC / 13
Lansoprazole or its saltsPDL I DEC / 13
Lanthanum saltsPDL

For human use - when sold for the treatment of hyperphosphatemia.

I DEC / 13
Lapatinib or its saltsPDL I DEC / 13
LaronidasePDL I DEC / 13
Larotrectinib or its salts PDL I OCT / 19
Ledipasvir or its saltsPDL I DEC / 14
Lefetamine and any Salt thereofC4 I JAN / 03
Leflunomide or its salts or derivativesPDL

Including but not limited to teriflunomide. 

I DEC / 13
LenalidomidePDL I DEC / 13
Lenvatinib or its saltsPDL I AUG / 16
Letermovir or its saltsPDL I DEC / 17
LetrozolePDL I DEC / 13
Leucovorin or its saltsPDL I DEC / 13
Leuprolide or its saltsPDL I DEC / 13
Levallorphane and its salts I SEP / 98
Levamisole or its saltsPDL

For human use. 

I DEC / 13
Levargorphane and its salts II SEP / 98
LevetiracetamPDL I DEC / 13
Levobunolol or its saltsPDL I DEC / 13
Levocabastine or its salts or derivativesPDL I DEC / 13
Levocarnitine or its salts or derivativesPDL

When sold for the treatment of primary or secondary levocarnitine deficiency.

I DEC / 13
Levodopa or its saltsPDL I DEC / 13
LevomethorphanN I JUN / 02
Levomilnacipran or its saltsPDL I JUN / 15
LevomoramideN I JUN / 02
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
LevophenacylmorphanN I JUN / 02
LevorphanolN I JUN / 02
LidocainePDL

For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.

I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Lifitegrast or its saltsPDL I MAR / 18
Linaclotide or its salts or derivativesPDL I DEC / 13
Linagliptin or its salts or derivativesPDL I DEC / 13
Lincomycin or its salts or derivativesPDL

Including but not limited to: Clindamycin 

I DEC / 18
Lindane II SEP / 98
Linezolid or its saltsPDL I DEC / 13
Liothyronine or its saltsPDL

For human use. 

I DEC / 13
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its saltsPDL I DEC / 13
Lisinopril or its salts or derivativesPDL I DEC / 13
Lithium or its saltsPDL I DEC / 13
Lixisenatide or its saltsPDL I JUN / 17
Lodoxamide or its salts or derivativesPDL

Including but not limited to Lodoxamide tromethamine.

I DEC / 13
Lomefloxacin or its saltsPDL I DEC / 13
Lomitapide or its saltsPDL I FEB / 14
LomustinePDL I DEC / 13
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
LopinavirPDL I DEC / 13
LoprazolamTS I JUN / 02
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorazepam and its saltsTS I SEP / 98
Lorlatinib or its salts PDL I MAR / 19
LormetazepamTS I JUN / 02
Losartan or its saltsPDL I DEC / 13
Losoxantrone or its saltsPDL I DEC / 13
LotilanerPDL

For veterinary use.

I MAR / 18
LovastatinPDL

Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.

I DEC / 14
Loxapine or its saltsPDL I DEC / 13
Lumacaftor or its salts or derivativesPDL I AUG / 16
LumiracoxibPDL I DEC / 13
Lurasidone or its saltsPDL I DEC / 13
Lutropin alfaPDL I DEC / 13
Lyme Disease vaccine I FEB / 02

79 résultats

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled